rethinkTHC Search
Menu
Study breakdown

Systematic review found nabiximols and CBD more promising than THC-based drugs for treating cannabis use disorder

Systematic ReviewModerate evidence
The takeaway

A systematic review of 8 RCTs found that endocannabinoid modulators (nabiximols, CBD, PF-04457845) showed broader efficacy for cannabis use disorder than cannabinoid receptor agonists (dronabinol, nabilone).

Addiction specialists seeking pharmacological options for CUD, and researchers developing medications for cannabis dependence.

Endocannabinoid modulators covered almost all aspects of CUD treatment

What the researchers found

Dronabinol reduced withdrawal symptoms but had limited broader efficacy. Nabilone failed to demonstrate efficacy. In contrast, nabiximols, CBD, and PF-04457845 reduced cannabis use and improved abstinence across multiple CUD outcomes. All medications were well-tolerated.

Why it matters

There are no approved medications for cannabis use disorder. This review identifies endocannabinoid modulation (rather than direct receptor agonism) as the more promising pharmacological strategy.

The numbers in context

8 RCTs, 667 participants. Dronabinol: reduced withdrawal only. Nabilone: no efficacy. Nabiximols: reduced use and improved abstinence. CBD: reduced use and improved abstinence. PF-04457845: reduced use and improved abstinence.

How the study worked

Systematic review of 8 randomized controlled trials evaluating medical cannabinoids for CUD (667 total participants). Outcomes assessed: cannabis use, abstinence, withdrawal, craving, treatment retention, and adverse events.

What this study cannot tell us

Only 8 trials available with 667 total participants. Small individual study sizes. Different doses, durations, and outcome measures across trials. Short follow-up periods.

How to read the evidence

Moderate: systematic review of RCTs, but limited by small number and size of included trials.

When this study was published

Published in 2022.

The bigger picture

The distinction between direct agonists (limited efficacy) and endocannabinoid modulators (broader efficacy) mirrors developments in other addiction fields and could shape the future of CUD pharmacotherapy.

Questions still open

  • What is the optimal dose and duration for nabiximols or CBD in CUD treatment? Would combining medications improve outcomes? Can these medications help people reduce use if complete abstinence is not the goal?

Common questions

Is there an approved medication for cannabis use disorder?
No. As of this review, there are no approved pharmacological treatments for CUD. This review identifies endocannabinoid modulators as the most promising direction.
What is the difference between agonists and modulators?
Agonists like dronabinol directly activate cannabinoid receptors (similar to THC). Modulators like nabiximols and CBD influence the endocannabinoid system more broadly, which appears to produce better treatment outcomes.
Was CBD effective for cannabis dependence?
Yes. CBD reduced cannabis use and improved abstinence in the included trials, suggesting it may help people reduce or stop using cannabis.

Read the original research

Cannabinoids in the Treatment of Cannabis Use Disorder: Systematic Review of Randomized Controlled Trials.

Frontiers in psychiatry, 13, 867878

Citation

Vuilleumier, Caroline; Scherbaum, Norbert; Bonnet, Udo; Roser, Patrik. (2022). Cannabinoids in the Treatment of Cannabis Use Disorder: Systematic Review of Randomized Controlled Trials.. Frontiers in psychiatry, 13, 867878. https://doi.org/10.3389/fpsyt.2022.867878

Explore the wider topic